Today: September 23, 2018, 12:37 pm

Recombinant Therapeutic Antibodies And Proteins Market Is Expected To Witness A Robust CAGR Of 12.2%

Integration of novel approaches and strategies to modify protein drug products is an important aspect.
Recombinant Therapeutic Antibodies
Recombinant Therapeutic Antibodies 2018-08-27 09:24:47
Integration of novel approaches and strategies to modify protein drug products is an important aspect. Advancements in recombinant protein technologies have allowed drug manufacturers and developers to adjust required functional characteristics of proteins of interest while maintaining product efficacy and safety.

Various recombinant technologies are currently in use to increase the half-life, functionality, and targeting of novel therapeutic protein drugs and increase product purity and volume. For instance, protein conjugation and derivatization methods, including albumin-fusion15, PEGylation and Fc-fusion are currently being used to extend a drug’s circulating half-life.

Moreover, increasing number of rare diseases significantly impacting public health is expected to drive growth of the recombinant therapeutic antibodies and proteins market size. According to National institute of Health (NIH) 2018 report, an estimated 7,000 different disorders collectively affect about 10% of the U.S. population, mainly young children and many lack effective treatments. In order to encourage the development of drugs that specifically address unmet medical needs, in 2013, an orphan designation was given for drugs used for the treatment of less than 200,000 patients in the U.S.

Get The Holistic SAMPLE With Research Methodology:

Monoclonal antibodies (mAbs) are most commonly used recombinant therapeutic products. The production of most monoclonal antibody products is easily amenable to effective platform-based approaches as antibodies are highly specific and the risk of unexpected safety issues in human clinical trials of mAb products is less as compared to other types of therapeutic products. The constant evaluation of monoclonal antibody drugs in new and expanded clinical indications results in constant demand for products in clinical studies ensuing increased sales in newly approved indications.

However, government regulations are stringent for production and approval of recombinant therapeutic drugs in order to ensure that these products are effective and safe.

Major players operating in the global recombinant therapeutic antibodies and proteins market include Abbott, Amgen Inc., Biogen Inc., Eli Lilly and Company, F. Hoffmann-La Roche, Johnson and Johnson, Merck & Co., Novo Nordisk, Pfizer Inc., and Sanofi S.A.

Click To Continue Reading On Recombinant Therapeutic Antibodies And Proteins Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Press Information
Coherent Market Insights
1001 4th Ave

Mr. Shah

# 400 Words
Related Articles
More From The Author
Ambulance Equipment Market to Surpass US$ 5,759.0 [..]
The Global Ambulance Equipment Market, by Equipment Type (Transportation Equipment, Burn Care Equipment, Diagnostic and Infection [..]
Cordyceps Sinensis Extract Market Growth and Analysis, [..]
Cordyceps Sinensis also called as ophiocordyceps sinensis is combination of parasitic fungus species and dead caterpillars that [..]
Peptide Therapeutics in Metabolic Disorders Market Opportunity [..]
Peptide therapeutics, due to their various advantages such as high stability, selectivity, safety, efficacy, bioavailability, and [..]
E-commerce Packaging Market Trends and Growth Outlook [..]
The e-commerce packaging market is bolstered by increasing e-commerce sales around the world. E-commerce has transformed retail [..]
Advanced Biofuel Market Insights, and Industry Forecast [..]
Advanced biofuels are fuels manufactured from various type of biomass, which includes waste from agricultural, urban, and other [..]
More From Health
Net Savings Link, Inc. (OTC: NSAV), a medical technology and software company, announced today that its subsidiary, Shanghai based [..]
Cadrock Secures US$5m for Therapy Targeting $35 [..]
- Enrolls first clinical trial patients in Sydney, Australia SYDNEY, Sept 4, 2018 - (ACN Newswire) - Cadrock Pty Ltd, [..]
NEGTEC launches Crowdfunding Portal promoting Regenerative Medicine to offer donation-based, cryptocurrency support for cutting-edge regenerative medicine and medical equipment TOKYO, [..]
Net Savings Link, Inc. (OTC: NSAV), a medical technology and software company, announced today that the Company has acquired a [..]
Novotech the Asia-Pacific CRO named Top 10 [..]
SYDNEY, Aug 23, 2018 - (ACN Newswire) - Asia-Pacific specialist CRO Novotech has been selected as one of the Top [..]

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.